Albertsons and Ionis lead a $3.02M insider-buy week
The July 27–August 3 screen found two qualifying officer/director-linked purchases totaling $3.02M: Albertsons after an outlook cut and Ionis ahead of a clinical catalyst calendar, while Scribe's IPO-linked rows were excluded.
The July 27–August 3, 2026 screen found two officer/director-linked purchase signals above $1 million, totaling $3.021 million. Albertsons EVP Thomas M. Moriarty supplied the larger buy after the grocer cut its fiscal-year outlook; Ionis Pharmaceuticals director Michael R. Hayden added shares immediately after the company’s second-quarter update.
The week also produced much larger apparent purchases at Scribe Therapeutics. Those rows matched the company’s IPO and concurrent private-placement price, so they are excluded from the clean total rather than treated as discretionary open-market conviction.
Screen window: July 27 at 8:00 a.m. through August 3 at 8:00 a.m., UTC-5 / US Eastern. Dollar values are gross reported purchase values. The latest stock marks below use the last regular-session close available before the cutoff, July 31. A Form 4 purchase code is a starting classification; it does not, by itself, prove that every row was executed on a public exchange.
The two qualifying signals
| Company | Insider and role | Purchase | July 31 mark | Context and cluster flag |
|---|---|---|---|---|
| Albertsons Companies (ACI) | Thomas M. Moriarty, EVP, M&A and Corporate Affairs | 170,500 shares at a weighted $11.509; $1,962,285 on July 27 12 | $11.58, about +0.6% from the weighted purchase price; market cap about $5.62B | Four days after an outlook cut. ACI CEO Susan Morris also bought about $449,938 on July 28, a supportive but below-threshold same-week purchase. Sector: Retail Trade; industry: Food Retail. 3 |
| Ionis Pharmaceuticals (IONS) | Michael R. Hayden, director; buyer identified in the filing representation as an entity associated with his spouse | 20,000 shares across July 30–31 at a weighted $52.94; $1,058,700 45 | $51.77, about -2.2% from the weighted purchase price; market cap about $8.60B | No second qualifying IONS buyer surfaced in the window. The purchases followed the July 29 Q2 release and precede several 2026 clinical milestones. Sector: Health Technology; industry: Pharmaceuticals: Major. 6 |
The combined figure is $3,020,985, rounded to $3.02 million in the headline. The marks are unrealized comparisons, not returns: they exclude fees, dividends, taxes, intraday execution differences and any later price movement.
1. ACI: a large operating executive buy after guidance was cut
Moriarty’s purchase is the cleaner conventional insider signal of the week. The Form 4 reports 170,500 directly held shares bought on July 27 in multiple price bands, with a weighted price of about $11.509 and a gross value of $1.962 million. The filing’s Rule 10b5-1 box was not checked. 1
The timing gives the transaction a clear, if not conclusive, backdrop. In its July 23 quarterly filing, Albertsons reported first-quarter net income of $84.7 million, down from $236.4 million a year earlier, while identical sales declined 0.8%. Management also reduced fiscal-year adjusted EPS guidance to $1.75–$1.85, from $2.22–$2.32, and adjusted EBITDA guidance to $3.550–$3.625 billion, from $3.850–$3.925 billion. 7
That makes Moriarty’s purchase a buy into a recently reset outlook, not a purchase made after an obvious guidance raise. The market had the information before the filing, and the purchase does not tell us whether the executive expects the new range to be conservative. It does show that an operating executive committed nearly $2 million while the stock was around $11.50.
Track record: Moriarty is untested in the available purchase history. No earlier visible P-code purchase provides a six- or twelve-month comparison that would support calling this a historically predictive signal. 8
Cluster flag: ACI CEO Susan Morris reported a separate purchase of about $449,938 on July 28. It reinforces the direction of the signal, but it does not change the qualifying count because it is below the channel’s $1 million threshold. The two buys should also not be treated as proof of coordinated conviction without more information about their execution and personal circumstances. 8
2. IONS: a director-linked repeat buy ahead of a catalyst calendar
The IONS purchase clears the threshold only when the July 30 and July 31 transactions are combined for the same insider-linked buyer. The filing representation identifies 15,000 shares bought on July 30 and another 5,000 on July 31, for 20,000 shares at a weighted price of about $52.94 and a gross value of $1.059 million. The buyer is an entity associated with Hayden’s spouse, so this is best described as a director-linked purchase rather than a simple direct personal account buy. 45
Ionis released its second-quarter results on July 29. The company reported $268 million of revenue, a $102 million operating loss, a $115 million net loss, and $2.1 billion in cash and short-term investments. Management said it remained on track for its 2026 guidance. The release also highlighted a busy development and commercial calendar: a September 22 PDUFA date for zilganersen, potential HORIZON results for pelacarsen, and an October 26 launch or PDUFA milestone for bepirovirsen, alongside sales of TRYNGOLZA and DAWNZERA. 9
The immediate mark is slightly negative: the July 31 close of $51.77 was about 2.2% below the weighted purchase price. That is too short a period to say anything about the trade’s outcome. The more useful distinction is between the purchase and the upcoming events: buying after a results release and before binary clinical milestones can reflect confidence, portfolio allocation or a risk decision that only the insider understands. It is not a forecast supplied by the filing.
Track record: the available history shows prior Hayden-linked purchases followed by positive marks at both six and twelve months in the two earlier checks available for comparison. The sample is small, and the historical association does not establish causation or guarantee that this purchase will behave similarly. 56
Cluster flag: no second IONS officer/director purchase above the threshold was identified in this window. This is therefore a repeat-buyer signal, not a same-week company-wide cluster.
What did not make the clean tally
SCTX: large rows matched IPO and private-placement terms
Scribe Therapeutics generated the largest apparent insider-buying numbers in the screen, including $15 million rows on July 27 and a much larger purchase reported on July 24. The reason they are not added to the weekly total is price provenance: Scribe priced its upsized IPO at $15 per share, then announced the July 27 closing of the IPO and a 500,000-share Sanofi private placement at the IPO price. Aggregate gross proceeds were about $155.51 million. 1011
When multiple Form 4 P rows land at the exact price of a newly announced offering, the filing code alone cannot distinguish public-market buying from an offering allocation. With no evidence in the available representations that resolves that question, SCTX is classified as financing-linked, not as discretionary open-market conviction.
MLPT and CATLU: holder or sponsor activity outside the signal
MapLight Therapeutics (MLPT) produced a roughly $15.3 million P row, but the buyer was a 10% holder rather than an executive or director. That fails the channel’s role filter, regardless of the dollar size. 12
Catalyst Acquisition Corp. (CATLU) showed a roughly $2.7 million sponsor/formation-style purchase at $10. Sponsor and SPAC-formation activity is not treated as a comparable operating-insider conviction signal. 13
Near misses and out-of-window rows
Several transactions were informative but did not qualify:
- ACI CEO Susan Morris: about $449,938 on July 28, below threshold.
- VFC CEO Darrell Bracken: about $492,752 on July 31, below threshold; an earlier VFC director purchase was outside the current window. 14
- ARTV: RA Capital’s July 29 purchase was about $455,726, while its larger July 21 purchase belonged to the prior screen. 15
- COE: the roughly $10.49 million Jack Huang purchase was dated July 14, before this edition’s window. 16
Bottom line
This is a small clean week: two qualifying signals, $3.02 million gross, and no confirmed same-company cluster above the threshold. ACI is the more unusual setup because an operating executive bought nearly $2 million after a sharp outlook reduction, with a smaller CEO purchase following one day later. IONS is the more event-sensitive setup: a director-linked repeat buyer added after earnings and ahead of several clinical milestones, but the stock had not yet moved above the purchase price by the cutoff.
Neither filing settles the investment case. The decision-relevant facts are the size and role of the buyer, whether the execution appears discretionary rather than financing-linked, the company backdrop at the time, and whether the insider has a record worth trusting. This week, Moriarty’s signal is historically untested; Hayden’s has a more encouraging but still small historical sample.
This article is an informational screen of public filings, not investment advice. Prices and market values are snapshots available before the August 3 cutoff and may have changed.
References
- 1ACI Form 4 filing
sec.gov
- 2ACI parsed Form 4
stocktitan.net
- 3ACI quote reference
finance.yahoo.com
- 4IONS Form 4 filing
sec.gov
- 5IONS insider screen
openinsider.com
- 6IONS quote reference
finance.yahoo.com
- 7Albertsons Q1 filing summary
stocktitan.net
- 8ACI insider history
openinsider.com
- 9Ionis Q2 2026 results and pipeline update
ir.ionis.com
- 10Scribe IPO pricing release
globenewswire.com
- 11Scribe IPO closing release
stocktitan.net
- 12MLPT insider screen
openinsider.com
- 13CATLU insider screen
openinsider.com
- 14VFC insider screen
openinsider.com
- 15ARTV insider screen
openinsider.com
- 16COE insider screen
openinsider.com
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.